ARWR - Company ID 0000879407
The table below shows ARROWHEAD PHARMACEUTICALS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q4 2024 | Q4 2023 | Q4 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $13.48M | -$146.27M | -$117.84M | -$75.52M | -$61.31M | -$38.92M |
| Capital expenditure | $2.15M | $7.52M | $68.66M | $38.91M | $5.78M | $4.27M |
| Investing cash flow | -$23.74M | $76.91M | $64.84M | -$80.69M | -$33.38M | $30.16M |
| Dividends paid | - | - | - |
ARROWHEAD PHARMACEUTICALS, INC. reported operating cash flow of $179.55M for fiscal year 2025. That is up 138.8% from -$462.85M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$64.43M (FY 2016) to $179.55M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$14.75M | $20.63M | $267.00K | $250.58M | $1.89M | $5.10M |